作者
Carol M Mangione, Michael J Barry, Wanda K Nicholson, Michael Cabana, David Chelmow, Tumaini Rucker Coker, Esa M Davis, Katrina E Donahue, Carlos Roberto Jaén, Martha Kubik, Li Li, Gbenga Ogedegbe, Lori Pbert, John M Ruiz, James Stevermer, John B Wong, US Preventive Services Task Force
发表日期
2022/8/23
来源
Jama
卷号
328
期号
8
页码范围
746-753
出版商
American Medical Association
简介
Importance
Cardiovascular disease (CVD) is the leading cause of morbidity and death in the US and is the cause of more than 1 of every 4 deaths. Coronary heart disease is the single leading cause of death and accounts for 43% of deaths attributable to CVD in the US. In 2019, an estimated 558 000 deaths were caused by coronary heart disease and 109 000 deaths were caused by ischemic stroke.
Objective
To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on the benefits and harms of statins for reducing CVD-related morbidity or mortality or all-cause mortality.
Population
Adults 40 years or older without a history of known CVD and who do not have signs and symptoms of CVD.
Evidence Assessment
The USPSTF concludes with moderate certainty that statin use for the prevention of CVD events and all-cause mortality in adults aged 40 …
学术搜索中的文章
CM Mangione, MJ Barry, WK Nicholson, M Cabana… - Jama, 2022